Literature DB >> 21114948

Patient preferences for obsessive-compulsive disorder treatment.

Sapana R Patel1, Helen Blair Simpson.   

Abstract

OBJECTIVE: To explore preferences for the treatment of obsessive-compulsive disorder (OCD). We hypothesized that OCD patients will select a combination of medication and psychotherapy as their most preferred choice overall.
METHOD: The authors designed a treatment-preference survey using 2 health economics methods, forced-choice and contingent-ranking methods, to elicit preferences for OCD treatment available in mainstream care (serotonin reuptake inhibitors [SRIs], exposure and response prevention [EX/RP], and their combination) and for novel treatments under development at OCD research clinics. This survey was given by telephone to 89 individuals with OCD who called the OCD research clinic at the New York State Psychiatric Institute between July 2008 and January 2009. Diagnosis of OCD was based on a telephone screening evaluation adapted from the Structured Clinical Interview for DSM-IV Axis I Disorders.
RESULTS: Most participants chose combination treatment (43%) or EX/RP (42%) over SRI medication (16%). Participants ranked investigational psychotherapy as their most-preferred novel treatment (endorsed by 48% of participants) and deep brain stimulation as their least-preferred novel treatment (endorsed by 77% of participants). Qualitative data suggest that prior treatment experience, concerns about medications, and logistical and practical concerns about treatment regimens affect preferences.
CONCLUSIONS: Patients with OCD have identifiable treatment preferences. In this sample of convenience, most preferred either combination treatment or psychotherapy. Future studies should investigate prospectively what modifies these preferences and how these preferences affect treatment outcome. © Copyright 2010 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21114948      PMCID: PMC3109740          DOI: 10.4088/JCP.09m05537blu

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  24 in total

1.  Treatment preferences affect the therapeutic alliance: implications for randomized controlled trials.

Authors:  Brian M Iacoviello; Kevin Scott McCarthy; Marna S Barrett; Moira Rynn; Robert Gallop; Jacques P Barber
Journal:  J Consult Clin Psychol       Date:  2007-02

2.  Can quality improvement programs for depression in primary care address patient preferences for treatment?

Authors:  M Dwight-Johnson; J Unutzer; C Sherbourne; L Tang; K B Wells
Journal:  Med Care       Date:  2001-09       Impact factor: 2.983

3.  Suffering in deference: a focus group study of older cardiac patients' preferences for treatment and perceptions of risk.

Authors:  C Kennelly; A Bowling
Journal:  Qual Health Care       Date:  2001-09

4.  Antidepressant drugs and generic counselling for treatment of major depression in primary care: randomised trial with patient preference arms.

Authors:  C Chilvers; M Dewey; K Fielding; V Gretton; P Miller; B Palmer; D Weller; R Churchill; I Williams; N Bedi; C Duggan; A Lee; G Harrison
Journal:  BMJ       Date:  2001-03-31

5.  Law enforcement preferences for PTSD treatment and crisis management alternatives.

Authors:  Carolyn Black Becker; Glenn Meyer; John S Price; Melissa M Graham; Ashley Arsena; David A Armstrong; Elizabeth Ramon
Journal:  Behav Res Ther       Date:  2009-01-17

6.  An analog study of patient preferences for exposure versus alternative treatments for posttraumatic stress disorder.

Authors:  Carolyn Black Becker; Ellen Darius; Katherine Schaumberg
Journal:  Behav Res Ther       Date:  2007-05-31

7.  "I need to talk about it": a qualitative analysis of trauma-exposed women's reasons for treatment choice.

Authors:  Frank N Angelo; Helen E Miller; Lori A Zoellner; Norah C Feeny
Journal:  Behav Ther       Date:  2007-10-18

8.  Patient preference as a moderator of outcome for chronic forms of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or their combination.

Authors:  James H Kocsis; Andrew C Leon; John C Markowitz; Rachel Manber; Bruce Arnow; Daniel N Klein; Michael E Thase
Journal:  J Clin Psychiatry       Date:  2009-01-13       Impact factor: 4.384

9.  Treatment preferences among depressed primary care patients.

Authors:  M Dwight-Johnson; C D Sherbourne; D Liao; K B Wells
Journal:  J Gen Intern Med       Date:  2000-08       Impact factor: 5.128

10.  Patients' depression treatment preferences and initiation, adherence, and outcome: a randomized primary care study.

Authors:  Patrick J Raue; Herbert C Schulberg; Moonseong Heo; Sibel Klimstra; Martha L Bruce
Journal:  Psychiatr Serv       Date:  2009-03       Impact factor: 4.157

View more
  13 in total

1.  Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.

Authors:  Helen Blair Simpson; Edna B Foa; Michael R Liebowitz; Jonathan D Huppert; Shawn Cahill; Michael J Maher; Carmen P McLean; James Bender; Sue M Marcus; Monnica T Williams; Jamie Weaver; Donna Vermes; Page E Van Meter; Carolyn I Rodriguez; Mark Powers; Anthony Pinto; Patricia Imms; Chang-Gyu Hahn; Raphael Campeas
Journal:  JAMA Psychiatry       Date:  2013-11       Impact factor: 21.596

2.  Benefits of CBT for OCD in pregnancy.

Authors:  Brittney F Dane; Eric A Storch
Journal:  Can Fam Physician       Date:  2014-05       Impact factor: 3.275

3.  Patient Preferences and Acceptability of Evidence-Based and Novel Treatments for Obsessive-Compulsive Disorder.

Authors:  Sapana R Patel; Hanga Galfavy; Marcia B Kimeldorf; Lisa B Dixon; Helen Blair Simpson
Journal:  Psychiatr Serv       Date:  2016-10-17       Impact factor: 3.084

4.  Acceptability of Treatments and Services for Individuals with Hoarding Behaviors.

Authors:  Carolyn I Rodriguez; Amanda Levinson; Sapana R Patel; Kim Rottier; Jordana Zwerling; Susan Essock; Lee Shuer; Randy O Frost; Helen Blair Simpson
Journal:  J Obsessive Compuls Relat Disord       Date:  2016-07-16       Impact factor: 1.677

Review 5.  Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review.

Authors:  R Kathryn McHugh; Sarah W Whitton; Andrew D Peckham; Jeffrey A Welge; Michael W Otto
Journal:  J Clin Psychiatry       Date:  2013-06       Impact factor: 4.384

6.  Acceptability, Feasibility, and Effectiveness of Internet-Based Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder in New York.

Authors:  Sapana R Patel; Michael G Wheaton; Erik Andersson; Christian Rück; Andrew B Schmidt; Christopher N La Lima; Hanga Galfavy; Olivia Pascucci; Robert W Myers; Lisa B Dixon; Helen Blair Simpson
Journal:  Behav Ther       Date:  2017-09-15

7.  Augmenting SRIs for Obsessive-Compulsive Disorder: Patient Preference for Risperidone Does Not Limit Effectiveness of Exposure and Ritual Prevention.

Authors:  Michael G Wheaton; Joseph K Carpenter; Eyal Kalanthroff; Edna B Foa; Helen Blair Simpson
Journal:  Psychother Psychosom       Date:  2016-08-12       Impact factor: 17.659

8.  Bothersome tics in patients with chronic tic disorders: Characteristics and individualized treatment response to behavior therapy.

Authors:  Joseph F McGuire; John Piacentini; Lawrence Scahill; Douglas W Woods; Robert Villarreal; Sabine Wilhelm; John T Walkup; Alan L Peterson
Journal:  Behav Res Ther       Date:  2015-05-12

9.  Current management of obsessive and phobic states.

Authors:  Serena Goljevscek; Livia A Carvalho
Journal:  Neuropsychiatr Dis Treat       Date:  2011-09-30       Impact factor: 2.570

10.  Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder.

Authors:  Christopher Pittenger; Brian P Brennan; Lorrin Koran; Carol A Mathews; Gerald Nestadt; Michele Pato; Katharine A Phillips; Carolyn I Rodriguez; H Blair Simpson; Petros Skapinakis; Dan J Stein; Eric A Storch
Journal:  Psychiatry Res       Date:  2021-03-04       Impact factor: 11.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.